Pipeline
Our lead candidate, AN2025 (buparlisib), will potential be the globally first approved second-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (r/m HNSCC) after disease progression with immunotherapy, which is an area of considerable unmet need.
Product
Indication
Discovery
IND Enabling
Phase Ia
Phase Ib
Phase II
Phase III
AN2025 (buparlisib)
oral pan-PI3K inhibitor
HNSCC 2/3L (+paclitaxel)
Global
PIK3CA mutant solid tumors 2/3L (+Tecentriq®+AN0025)
Global
AN0025 (palupiprant)
oral EP4 antagonist
TNBC, NSCLC, UC, MSS CRC and CC 2/3L (+Keytruda®)
Global (Excl. Japan, South Korea and partial SEA countries)
AN4005
oral PD-L1 inhibitor
Advanced tumors
Global (Excl. greater China)
AN8025
T cell/APC modulator
Advanced tumors
Global
AN1025
oral β-catenin degrader
Advanced tumors
Global
AN9025
oral pan-KRAS inhibitor
Advanced tumors
Global

Abbreviation: HNSCC = Head and neck squamous cell carcinoma; TNBC =  Triple Negative Breast Cancer; NSCLC = Non-Small Cell Lung Cancer; UC = urothelial cancer; MSS CRC = Microsatellite Stable Colorectal Cancer; CC = cervical cancer